{
    "clinical_study": {
        "@rank": "35", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      Evaluate the safety and efficacy of long term recombinant human insulin-like growth factor I\n      in children with hyperinsulinism."
        }, 
        "brief_title": "Phase II Long Term, Randomized Study of Recombinant Human Insulin-Like Growth Factor I in Children With Hyperinsulinism", 
        "condition": "Hyperinsulinism", 
        "condition_browse": {
            "mesh_term": "Hyperinsulinism"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, cross-over study.\n\n      Patients are randomized to receive recombinant human insulin-like growth factor I (IGF-I) or\n      placebo subcutaneously twice daily for 4 weeks.  After a 2 week washout period, patients are\n      crossed over to the other regimen for an additional 4 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Diagnosis of hyperinsulinism (i.e., evidence of fasting\n        hypoglycemia with inadequate suppression of insulin, normal pituitary and adrenal\n        function, and increased insulin action) Suboptimal control of blood sugar (i.e., inability\n        to fast at least 10 hours with a blood sugar of 60 mg/dL or greater) --Prior/Concurrent\n        Therapy-- See Disease Characteristics --Patient Characteristics-- Performance status: Not\n        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other:\n        No other major medical conditions No known adverse reaction to recombinant human\n        insulin-like growth factor I"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": "16", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004700", 
            "org_study_id": "199/13382", 
            "secondary_id": "CHP-FDR001181-DBPC"
        }, 
        "intervention": {
            "intervention_name": "insulin-like growth factor I", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Complement Factor I", 
                "Mitogens", 
                "Insulin"
            ]
        }, 
        "keyword": [
            "endocrine disorders", 
            "hyperinsulinism", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Children's Hospital of Philadelphia", 
            "last_name": "Pinchas Cohen", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004700"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Children's Hospital of Philadelphia", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "May 1998", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1999"
    }, 
    "geocoordinates": {}
}